The Company Aims to Quadruple its Production Capacity
Established in 1928, Ali Raif İlaç Sanayi has a deep-rooted history and an important place in the Turkish pharmaceutical industry with its 58 years of experience in the field. The company has now taken an important step in line with its growth targets and broke ground for its new production facility in İkitelli, Istanbul.
As a company with 93 years of history, 58 years of pharmaceutical experience, and 100 percent domestic capital, Ali Raif İlaç broke ground for a new production facility in İkitelli, Istanbul. Due to the pandemic, only the company’s Board of Directors, a limited number of employees, and business partners attended the groundbreaking ceremony held on June 14.
This new facility is planned to be completed by the end of 2023. With this new facility, Ali Raif İlaç aims to quadruple its current production capacity, increase employment by 30 percent, and boost exports.
The facility will be built on an area of 24,000 square meters with an investment cost of €100 million. Furthermore, plans are in place to make all production processes zero waste.
In the new factory, Ali Raif İlaç will incorporate additional liquid, pomade, layered tablet, pellet tablet and powder-filling production lines.
Speaking at the groundbreaking ceremony, Ali Raif İlaç CEO Muzaffer Bal said: “We had an empty piece of land in December 1993. We were extremely excited that day, just as we were when we opened our first factory in 1999. Since then, we have been producing our products here in line with the Good Manufacturing Practices. We bought the land for our second factory on December 31, 2019 and began our work with Sayar Group in February 2020. We focused on specifying our needs and preparing projects that will lead us to the future. This magnificent project was more than double the size of our existing facilities and was built on an area of 24,000 square meters. With this step, we aim to quadruple our production capacity. Our new facility, which we plan to open at the end of 2023, is expected to have an investment cost of approximately €100 million. From now on, all mentions of our İkitelli Facility will refer to our İkitelli Complex, as we now have two factories here. As soon as the factory is completed, we will relocate our R&D center and modernize our current facility so that we can commence the development of new indications, new formulations, and new drugs as soon as possible. The new factory will also increase our workforce by 30 percent. It is with great pride that we announce our plans to make all of our production processes zero-waste, in light of our “Respect for People” value and our mission to “Add Value to Life.”
Expressing her feelings, Ali Raif İlaç General Manager Nihal Arslan said: “Our company has adopted respect for people, reliability, success, and innovation as its core principles since 1928. We have continued to grow and carry the Turkish pharmaceutical industry and Turkish medicine into the future since 1963. We built our first factory 28 years ago and, with the great support of our employees, we have successfully carried the Ali Raif brand to this day. We continue to grow significantly each year. We have now broke ground for our new facility.
We are very excited and proud. From now on, our priority is to swiftly complete this factory so we can start production, expand our production line, increase our capacity, and expand our product portfolio. In this new factory, we will be incorporating additional liquid, pomade, layered tablet, pellet tablet and powder-filling production lines. We set out to make this factory a world-class facility. Our dream is to reinforce our position in the Turkish pharmaceutical market and become a successful player in the global market. I would also like to emphasize our willingness to collaborate, such as in contract manufacturing, as soon as our factory becomes fully operational. Although the COVID-19 measures prevented us from physically attending the groundbreaking ceremony of this great investment, this honor and success belongs to all our employees.